Skip to content

Impact of Long COVID on Myasthenia Gravis Exacerbation: A Prospective Cohort Study

To explore the factors associated with myasthenia gravis relapseand prevention measures in the context of COVID-19 pandemic

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087937
Enrollment
Unknown
Registered
2024-08-07
Start date
2022-12-05
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia gravis

Interventions

MG exacerbation group:none
Non MG exacerbation group:none

Sponsors

The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4.5 Years to 81 Years

Inclusion criteria

Inclusion criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Type of Participant and Disease Characteristics Patients diagnosed definitively with MG, based on clinical presentations that align with national guidelines. 1)Muscle fatigability and weakness 2)Presence of anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific kinase (anti-MuSK) antibodies 3)More than 10% decrement at repetitive nerve stimulation 4)Consistent improvement with anticholinesterase medications 2. For MG individuals co-infected with COVID-19, the COVID-19 diagnosis was determined according to previous study 1) Positive SARS-CoV-2 result obtained through real-time fluorescent PCR analysis of throat swab specimens 2) Positive COVID-19 antigen test or serology 3. Informed Consent 1) Participants who understand and agree to comply with planned study procedures 2) Capable of giving signed informed consent as described in protocol Supplementary Appendix Text 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion criteria: 1) Cases with other definitive reasons accounted for MG worsening during this COVID-19 pandemic period were excluded. 2) The unclear diagnosis of both MG and COVID-19. 3) Failure to complete follow-up. 4) Unable to complete the associated questionnaires, comprehensive disease evaluation.

Design outcomes

Primary

MeasureTime frame
Symptoms of Myasthenia gravis exacerbation;MG-ADL score;

Secondary

MeasureTime frame
1-year mortality in myasthenia gravis patients;

Countries

China

Contacts

Public ContactYan Li

The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

475961266@qq.com+86 181 1183 9883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026